Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer

The study will be conducted as an open-label randomized two-arm multicenter Phase II study.
Patients will be randomized in a 1:1 ratio into one of the two treatment arms within each
stratum: AEZS-108 (267 mg/m2 every 21 calendar days) (Arm A) OR SSCC (Arm B) at discretion of
treating oncologist cycled every 21 calendar days.

Stratified randomization will be used with number of prior lines of therapies (1-2 versus
>2). Tumor assessment will be repeated every 2 cycles. At the time of disease progression,
Arm B patients may be crossed over to AEZS-108 as long as none of the exclusion criteria for
study entry apply. Particularly, LVEF ≥50% is required, and patients failing on liposomal
doxorubicin cannot be crossed over to AEZS-108.

Analysis of the main study endpoint, PFS, will follow a group sequential design with one
interim and one final analysis utilizing the O'Brien-Fleming stopping boundaries procedure.
The study will be terminated for futility if the lower bound is crossed and for superiority
if the upper bound is crossed. The sponsor may also terminate the study for futility based on
other considerations such as safety.

Inclusion Criteria:

1. Women ≥ 18 years of age

2. Histologically documented breast cancer (either primary or metastatic site) that is
(i) ER-negative (0), (ii) PR-negative (0), and (iii) HER2-negative, defined by IHC
(immunohistochemistry; IHC 0/1, non-overexpressing) or FISH (fluorescence in situ
hybridization; FISH negative) or CISH (chromogen in situ hybridization; CISH
negative).

3. Expression of LHRH receptor confirmed by IHC on archival (or current biopsy of breast
tumor or metastatic site) breast cancer tissue

4. Progressive disease after failure of 1 to 3 prior chemotherapy regimens for recurrent
or metastatic (Stage IV) disease (prior adjuvant/neoadjuvant therapy is allowed)

5. Measurable disease by RECIST 1.1 criteria; at least one target lesion that has not
been previously irradiated.

Exclusion Criteria:

1. Eastern Cooperative Oncology Group (ECOG) performance status > 2

2. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia or recent myocardial infarction (within 6 months of enrollment)

3. Leptomeningeal disease or brain metastases requiring steroids or other therapeutic
intervention

4. Left ventricular ejection fraction (LVEF) < 50 %, determined by echocardiogram or MUGA
scan

5. Compromised organ or marrow function as evidenced by any of the following:

- thrombocyte count: < 100x109/L

- absolute neutrophil count (ANC): < 1.5x109/L

- hemoglobin: < 6.0 mmol/L (< 9 g/100 mL)

- AS(A)T, AL(A)T: > 2.5 times upper limit of normal range (ULN) (> 5x ULN if
clearly related to liver metastases)

- bilirubin: > 1.5 mg/dL

- creatinine: > 1.5 mg/dL or creatinine clearance < 40 mL/min.

6. Systemic anticancer therapy or radiotherapy within 21 calendar days of the first dose
of study drug*)

* also excluded are patients with anticipated ongoing concomitant anticancer therapy
during the study

7. Prior exposure to anthracyclines or anthracenediones for the treatment of metastatic
breast cancer including liposomal doxorubicin (Doxil), doxorubicin, daunorubicin, or
mitoxantrone

8. Prior adjuvant anthracyclines with a cumulative anthracycline dose ≥ 300 mg/m2

9. Ongoing therapeutic anticoagulation

10. Patients who are not surgically sterile or post-menopausal must agree to use for the
duration of the study reliable methods of birth control defined as:

- complete abstinence

- any intrauterine device (IUD) with published data showing that the lowest
expected failure rate is < 1 % per year, or

- any other methods with published data showing that the lowest expected failure
rate is less than 1 % per year

11. Investigational therapy within 30 calendar days of the first scheduled day of protocol
treatment (investigational therapy is defined as treatment for which there is
currently no regulatory authority approved indication).